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Rifampicin Reduces Plasma Concentrations
of Moxifloxacin in Patients with Tuberculosis
H. M. J. Nijland,1,3,a R. Ruslami,4,a A. Juwono Suroto,5 D. M. Burger,1,3 B. Alisjahbana,6 R. van Crevel,2,3
and R. E. Aarnoutse1,3
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Background. The long duration of the current tuberculosis (TB) treatment is demanding and warrants the
development of new drugs. Moxifloxacin shows promising results and may be combined with rifampicin to shorten
the duration of TB treatment. Rifampicin induces the phase II metabolic enzymes that are involved in the
biotransformation of moxifloxacin. Therefore, the interaction between rifampicin and moxifloxacin should be
investigated.
Patients and methods. Nineteen Indonesian patients with pulmonary TB who were in the last month of their
TB treatment completed a 1-arm, 2-period, fixed-order pharmacokinetic study. In phase 1 of the study, they
received 400 mg of moxifloxacin every day for 5 days in addition to 450 mg of rifampicin and 600 mg of isoniazid
3 times per week. In phase 2 of the study, after a 1-month washout period, patients received moxifloxacin for
another 5 days (without rifampicin and isoniazid). A 24-h pharmacokinetic curve for moxifloxacin was recorded
on the last day of both study periods, and its pharmacokinetic parameters were evaluated for an interaction with
rifampicin, using a bioequivalence approach.
Results. Coadministration of moxifloxacin with rifampicin and isoniazid resulted in an almost uniform decrease
in moxifloxacin exposure (in 18 of 19 patients). The geometric means for the ratio of phase 1 area under the
curve to phase 2 area under the curve and for the ratio of phase 1 peak plasma concentration to phase 2 peak
plasma concentration were 0.69 (90% confidence interval, 0.65–0.74) and 0.68 (90% confidence interval, 0.64–
0.73), respectively. The median time to reach peak plasma concentration for moxifloxacin was prolonged from 1
h to 2.5 h when combined with rifampicin and isoniazid ( ).Pp .003
Conclusions. Coadministration of moxifloxacin with intermittently administered rifampicin and isoniazid re-
sults in reduced moxifloxacin plasma concentrations, which is most likely the result of induced glucuronidation
or sulphation by rifampicin. Further studies are warranted to evaluate the impact of the interaction on the outcome
of TB treatment.
Worldwide, tuberculosis (TB) causes ∼2 million deaths
each year [1, 2]. The main problem with TB treatment
is its long duration (6 months), which is very de-
manding in terms of adherence and tolerability. New
TB drugs may help to shorten the treatment duration.
Following a study involving the quinolone ofloxacin
[3], the quinolone antibiotics have raised great interest
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because of the possibility that their use will decrease
the duration of TB treatment.
Newer-generation quinolones possess even greater in
vitro activity against Mycobacterium tuberculosis than
ofloxacin. The quinolone moxifloxacin, currently rec-
ommended for the treatment of multidrug-resistant TB
[4], shows the highest in vitro activity against M. tu-
berculosis [5]. Moxifloxacin has shown the potential to
shorten TB treatment by 2 months when used as a
substitute for isoniazid in a murine model [6, 7]. Stud-
ies involving humans show that the early bactericidal
activity of moxifloxacin is comparable to that of iso-
niazid [8, 9]. Furthermore, it has been shown that mox-
ifloxacin is safe for long-term use in patients with TB
[10]. A recent study evaluated the effect of moxifloxacin
versus ethambutol (both administered in combination
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Figure 1. Study design, showing dosing schedules for phase 1 and phase 2 of the study. The washout phase had a duration of 1 month. Phase 1
took place in the last month of tuberculosis treatment; therefore, steady state was already achieved for rifampicin and isoniazid at the start of the
study. Phase 2 took place 1 month after the end of tuberculosis treatment. INH, isoniazid (600 mg administered 3 times per week); MXF, moxifloxacin
(400 mg administered once daily); PK, pharmacokinetic assessment; RIF, rifampicin (450 mg administered 3 times per week); S, screening.
with other TB drugs) on sputum conversion at 2 months [11],
and similar studies are underway.
Rifampicin is the strongest known inducer of cytochrome
P450 isoenzymes. No pharmacokinetic interaction between
moxifloxacin and rifampicin is anticipated at the level of phase
I metabolism, because moxifloxacin is entirely metabolized by
the phase II metabolizing processes of glucuronidation and
sulphation. However, rifampicin also induces the phase II en-
zymes uridine diphoshate glucuronosyltransferase and sulpho-
transferase, which may possibly affect the area under the curve
(AUC) and peak plasma concentrations (Cmax) of moxifloxacin.
This interaction could also be of relevance in developed coun-
tries when moxifloxacin and rifampicin are combined in TB
treatment (for example, for treatment of patients who are in-
tolerant of first-line TB drugs or who have extensive TB that
is isoniazid monoresistant [12]). The objective of this phar-
macokinetic study was to assess the interaction between rifam-
picin and moxifloxacin.
PATIENTS AND METHODS
Subjects. Study subjects were Indonesian patients with pul-
monary TB who were in the last month of the continuation
phase of TB treatment. All study subjects had a body weight
135 kg, were 18–55 years of age, and had normal electrocar-
diogram findings. All patients had a satisfactory response to
treatment, and none had sputum smear results positive for TB
after 2 months of treatment. Subjects were excluded from the
study if they were pregnant or lactating; had a relevant history
or condition that might interfere with drug absorption, distri-
bution, metabolism, or excretion; had heart rhythm distur-
bances; had a history of seizures or epilepsy; had a glucose 6
phosphate dehydrogenase deficiency; had hypersensitivity to
quinolones; had experienced tendon disorders related to flu-
oroquinolone treatment; had hypokalemia; or had use of any
drug that might interact with moxifloxacin.
Study design. This study was an open-label, multiple-dose,
1-arm, 2-period, fixed-order pharmacokinetic interaction study
and was performed in an outpatient clinic in Bandung, In-
donesia. According to the National Tuberculosis Program of
Indonesia, the continuation phase of TB treatment consists of
600 mg of isoniazid and 450 mg of rifampicin, both admin-
istered 3 times per week. The dose of rifampicin is lower than
the usual 600-mg dose because of the low mean body weight
of Indonesian people. Because all patients were in the last
month of TB treatment, steady state for rifampicin and iso-
niazid was already achieved at the start of the study. In addition
to regular TB treatment, subjects were given 400 mg of mox-
ifloxacin every day for 5 days to attain steady state of this drug
(figure 1) [13]. After completion of TB treatment and a washout
period of 1 month, patients received 400 mg of moxifloxacin
per day for another 5 days. A full pharmacokinetic curve was
recorded at day 5 in both phases of the study. Intake of study
medication was observed on days 1, 3, and 5 in each phase.
Furthermore, adherence to study medication was evaluated by
counting capsules and by the use of Medication Event Moni-
toring System vials. These vials contain microprocessors that
register the date and time of each opening of the vial. All
patients gave written informed consent, and both the Ethical
Review Board of Hasan Sadikin Hospital, Padjadjaran Univer-
sity (Bandung, Indonesia), and the Advisory Board of Radboud
University Nijmegen Medical Centre (Nijmegen, The Nether-
lands) approved the study.
Experimental procedures. Steady state pharmacokinetic
parameters were assessed on the last day in both phases. Patients
were asked to refrain from any food intake from 11 pm the
preceding night until standardized lunch was provided, 4 h
after intake of study medication. Study drugs (moxifloxacin in
phase 1 and phase 2, plus rifampicin and isoniazid in phase 1
only) were taken together on an empty stomach. To assess
plasma concentrations of moxifloxacin and rifampicin, serial
blood sampling was performed before intake and at 0.5, 1, 1.5,
2, 2.5, 3, 4, 6, 8, 12, and 24 h after intake of the drugs. All
blood samples were centrifuged immediately and frozen at
20C within 20 min after collection. Afterwards, all samples
 at K
atholieke U
niversiteit on July 9, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Rifampicin Reduces Moxifloxacin Levels • CID 2007:45 (15 October) • 1003
Table 1. Steady state pharmacokinetic results for moxifloxacin in a cohort of 19
patients.
Pharmacokinetic parameter
Geometric mean value (range)
Geometric mean ratio
of period 1 to
period 2 (90% CI)Phase 1a Phase 2b
AUC0–24 h, mg  h/L 33.3 (25.1–55.5) 48.2 (37.2–60.5) 0.69 (0.65–0.74)
Cmax, mg/L 3.2 (2.5–4.5) 4.7 (3.4–6.0) 0.68 (0.64–0.73)
Cmin, mg/L 0.38 (0.18–0.78) 0.78 (0.51–1.1) 0.38 (0.31– 0.48)
Tmax, h 2.5 (0.5–6.0)
c 1.00 (0.5–3.0)d 0.003d
CL/F, L/h 12.0 (7.2–16.0) 8.3 (6.6–10.8) 1.45 (1.35–1.54)
Vd/F, L 123 (83–187) 119 (8.4–179) 1.04 (0.98–1.09)
T1/2, h 7.1 (5.0–9.6) 9.9 (7.4–14.0) 0.72 (0.68–0.75)
NOTE. AUC0–24 h, 24-h area under the concentration-time curve; Cmax, highest observed plasma con-
centration; Cmin, trough plasma concentration at 24 h after intake of study medication; CL/F, total clearance;
F, bioavailability; tmax, time at which Cmax occurs; t1/2 elimination half-life; Vd/F, volume of distribution.
a Phase 1 therapy consisted of a combination of 400 mg of moxifloxacin administered once daily and
600 mg of isoniazid and 450 mg of rifampicin administered 3 times weekly.
b Phase 2 therapy consisted of 400 mg of moxifloxacin administered once daily.
c Median and range.
d By Wilcoxon signed-rank test.
were transferred to 80C. Samples were shipped on dry ice
to The Netherlands for bioanalysis.
Plasma concentrations. Moxifloxacin plasma concentra-
tions were measured by means of a validated high-performance
liquid chromatography method with fluorescence detection.
Accuracy was 195% for the moxifloxacin standard concentra-
tions of 0.074 mg/L, 0.15 mg/L, 0.74 mg/L, and 7.4 mg/L.
Intraday precision and between-day precision (expressed as co-
efficient of variation) ranged from 1.4% to 5.4% and from 0.2%
to 3.9%, dependent on the concentration. Ninety-eight drugs
were tested for interference. The lower and upper limits of
quantitation were 0.03 mg/L and 10.0 mg/L, respectively. Mox-
ifloxacin in plasma is stable at 20C and 80C for at least
12 months. The plasma concentrations of rifampicin and de-
sacetylrifampicin were analyzed by a previously described val-
idated high-performance liquid chromatography UV method
[14]. Accuracy was 99.8%, 100.4%, and 100.4% for the rifam-
picin standard concentrations of 2.9 mg/L, 9.5 mg/L, and 23.7
mg/L, respectively. The accuracy of the desacetylrifampicin
standard concentrations of 0.09 mg/L, 2.25 mg/L, and 27.0 mg/
L was 103.9%, 102.4%, and 102.6%, respectively. Intraday pre-
cision and between-day precision ranged from 0.7% to 1.1%
and from 0.1% to 0.6%, respectively, for rifampicin and from
0.9% to 2.9% and from 0.5 to 3.6%, respectively, for desace-
tylrifampicin. Rifampicin in plasma is stable for at least 16
months at20C and80C. Concentrations of isoniazid were
not assessed, because measurement of this drug was not relevant
to the study.
Tolerability and safety. Tolerability and safety were as-
sessed on days 1, 3, and 5 in both study phases. Patients were
actively questioned about the occurrence of the known adverse
effects of moxifloxacin. Clinical chemistry and hematological
tests and evaluations of vital signs (i.e., heart rate and blood
pressure) and electrocardiograms were performed on the same
days. All possible adverse events were graded according to the
Common Toxicity Criteria, version 2.0 [15].
Pharmacokinetic and statistical analysis. All pharmaco-
kinetic evaluations for rifampicin and moxifloxacin were per-
formed using noncompartmental methods with WinNonLin
software, version 4.1 (Pharsight). The highest observed plasma
concentration was defined as Cmax, with the corresponding time
as tmax. Cmin was the plasma concentration at 24 h after intake
of study medication. The AUC0–24 h was calculated using the
log-linear trapezoidal rule from 0 up to the last concentration.
The terminal log-linear period (log C vs. t) was based on the
last data points ( ). The absolute value of the slope wasn 3
calculated by least-squares linear regression analysis. b is the
first-order elimination rate constant. Terminal half-life was ob-
tained by the equation 0.693/b. The apparent clearance of the
drug (Cl/F) was calculated by the formula dose/AUC0–24 h. The
volume of distribution (Vd/F) was calculated by the equation
Cl/F/[b].
The sample size of the study was derived from the main
pharmacokinetic parameter, the AUC0–24 h of moxifloxacin, and
was determined for a data analysis that is similar to a within-
subject 2-period bioequivalence study [16], as recommended
for interaction studies. The desired power of the study was
90%, and the within-subject coefficient of variation for the
logarithmically transformed AUC0–24 h of moxifloxacin was con-
servatively estimated to be 15%. On the basis of these data, at
least 12 subjects were required. Because this was an estimation
and dropouts were expected, 22 patients were enrolled in the
study.
The MIC of moxifloxacin for M. tuberculosis (0.5 mg/L [17])
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Figure 2. Steady state 24-h area under the curve (AUC0–24 h) of moxifloxacin when administered once daily (phase 2) and when combined with
administration of rifampicin and isoniazid 3 times per week (phase 1) in a cohort of 19 patients.
was used to calculate the pharmacodynamic parameters AUC0–
24 h:MIC and Cmax:MIC. The number of patients who reached
the targets of AUC0–24 h:MIC and Cmax:MIC ratios of 100 and
10, respectively [18–23], was compared using the x2 test. The
mutant prevention concentration (MPC) for moxifloxacin in
TB treatment was set at 2.5 mg/L [24], uncorrected for protein
binding. Time greater than MPC was the time during which
the moxifloxacin concentration was above the MPC.
All statistical evaluations were performed with SPSS for Win-
dows, version 12.0.1 (SPSS). Pharmacokinetic parameters were
log-transformed before statistical analysis. The values for tmax
were not transformed and were compared using the Wilcoxon
signed-rank test. Using a bioequivalence approach for the eval-
uation of the interaction, the 90% CI of the geometric mean
ratios AUCphase 1:AUC phase 2 and phase 1 Cmax:phase 2 Cmax
should be between 80% and 125% to conclude the absence of
an interaction. P values !.05 were considered to be statistically
significant in all other analyses.
RESULTS
Patients. Twenty-two subjects were included in the study.
Two of the subjects dropped out during the second phase of
the study, one for medical reasons unrelated to the study and
the other for personal reasons. A third subject was excluded
from all analyses after the study, because this subject missed 1
dose on the day preceding the pharmacokinetic assessment in
phase 2.
The diagnosis of TB in the study subjects was based on the
following clinical symptoms: history of cough (in 100% of
subjects), shortness of breath (50%), fever (60%), night sweats
(65%), and weight loss (65%). All patients had abnormal ra-
diograph findings and had cultures positive for M. tuberculosis
at initiation of TB treatment. The mean age of the 19 study
subjects who completed the study (6 of whom were female)
was 30 years (range, 20–55 years), and the mean weight of the
subjects was 55 kg (range, 38–80 kg) at the first day of phar-
macokinetic assessment. Type 2 diabetes was present in 1 pa-
tient, but the patient did not take antidiabetic medication. Ad-
herence was excellent in all subjects: all 19 patients were 100%
adherent.
Pharmacokinetics and safety of moxifloxacin and
rifampicin. The geometric mean for the ratio AUCphase 1:
AUCphase 2 of moxifloxacin was 0.69 (90% CI, 0.65–0.74). Sim-
ilar figures were shown for moxifloxacin Cmax (table 1). Mox-
ifloxacin Cmin showed a stronger decrease (geometric mean ra-
tio, 0.38) when coadministered with rifampicin and isoniazid.
As a result, bioequivalence for the combination of rifampicin,
isoniazid, and moxifloxacin, compared with moxifloxacin
alone, cannot be concluded. Moxifloxacin exposure decreased
in all but 1 subject (figure 2). Moxifloxacin tmax was prolonged
when combined with rifampicin and isoniazid ( ; figurePp .003
3). A relatively small interindividual variability in pharmaco-
kinetic parameters for moxifloxacin was observed, which has
been described elsewhere [25].
The AUC24 h for moxifloxacin without rifampicin (in phase
2) did not correlate with the relative difference between the 2
phases (i.e., AUC phase 2:AUC phase 1; Pearson correlation coeffi-
cient, 0.195; ).Pp .423
The geometric mean values for AUC0–24 h:MIC and Cmax:MIC
for moxifloxacin in phase 2 approached the desired values for
fast growing bacilli (geometric mean values, 96.4 [range, 74.4–
121] and 9.5 [range, 6.8–12.1], respectively), in contrast with
the values in phase 1 (geometric mean values, 66.7 [range, 50.3–
111] and 6.5 [4.9–9.1], respectively; ). When moxiflox-P ! .01
acin was given alone (in phase 2), 9 (47%) of 19 participants
reached an AUC0–24 h:MIC that was 1100, compared with only
1 patient (5%) when moxifloxacin was combined with rifam-
picin and isoniazid in phase 1. Results were similar with respect
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Figure 3. Mean (SD) moxifloxacin steady state plasma concentrations versus time (19 patients). Open squares indicate data for patients receiving
400 mg of moxifloxacin administered once daily. Closed squares indicate data for patients receiving a combination of 400 mg of moxifloxacin administered
once daily and 450 mg of rifampicin and 600 mg of isoniazid administered 3 times per week. Bars indicate standard deviation.
to the Cmax:MIC ratio. The median time during which the
moxifloxacin concentration was greater than the MPC was 5.5
h (range, 2.5–7.5 h) when given alone in phase 2, compared
with 2 h (range, 0–7.5 h) when combined with rifampicin and
isoniazid ( ).P ! .01
The pharmacokinetic parameters of rifampicin and its main
metabolite (desacetylrifampicin) are shown in table 2. No sig-
nificant correlation was found between exposure to rifampicin
(AUC0–24) and the ratio of AUC phase 2:AUC phase 1 for moxiflox-
acin (Pearson correlation coefficient, 0.168; ). The 1Pp .493
diabetic patient showed average exposure to rifampicin, al-
though plasma rifampicin concentrations have been found to
be reduced in patients with type 2 diabetes [26]. The patients
experienced only grade I adverse events, and no laboratory
abnormalities were detected.
DISCUSSION
To our knowledge, this report presents the first pharmacoki-
netic data regarding the use of moxifloxacin to treat patients
with TB. Our study demonstrates that steady state plasma con-
centrations of moxifloxacin are significantly reduced when
moxifloxacin is combined with rifampicin and isoniazid.
The interaction is expected to result from an increase in phase
II metabolism caused by rifampicin, because moxifloxacin does
not undergo phase I oxidative metabolism [13]. No interference
of isoniazid in the metabolism of moxifloxacin is anticipated,
because isoniazid is only known to affect cytochrome P450–
mediated metabolism [27]. Rifampicin is known to be a very
strong inducer of CYP-P450 isoenzymes. It is probably less well
known that this drug also induces phase II metabolism. More
specifically, rifampicin induces uridine diphoshate glucurono-
syltransferase and sulphotransferase, thereby reducing plasma
concentrations of rofecoxib, mycophenolate mofetil, lamotri-
gine, zidovudine, and propafenone [13, 28–34]. A similar
mechanism may be involved in the interaction with moxiflox-
acin, because this drug undergoes phase II biotransformation
and will be excreted as a sulpho-compound or as glucuronide
via the kidneys (2.5% and 14%, respectively) and the feces (34%
and 14%, respectively) [35]. Recently, it was found that, in
healthy volunteers, rifampicin mainly induces the sulphation
pathway of moxifloxacin [36]. Of note, the difference in tmax
between phases could be suggestive for a role of P-glycoprotein.
The expression of P-glycoprotein in intestinal cells is induced
by rifampicin, and moxifloxacin could be a substrate of this
protein [37]. However, induced sulphation or glucuronidation
could also cause this difference.
The AUC0–24 h and Cmax of moxifloxacin showed mean de-
creases of 31% and 32%, respectively. This reduction in plasma
concentrations can be characterized as modest, and similar re-
ductions in AUC (27%) and tmax were found in a similar study
involving healthy subjects [36]. Strikingly, Cmax was found to
be unaffected by rifampicin in this study [36]. In the current
study, the reduction of moxifloxacin plasma concentrations oc-
curred almost uniformly, in all but 1 of the study subjects.
Daily dosing of rifampicin instead of intermittent dosing could
possibly amplify the extent of this interaction. For gram-neg-
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Table 2. Pharmacokinetic results for rifampicin and its main
metabolite, desacetylrifampicin, in a cohort of 19 patients.
Drug or metabolite,
pharmacokinetic parameter
Geometric
mean value (range)
Rifampicin
AUC0–24 h, mg  h/L 35.7 (10.4–55.4)
Cmax, mg/L 6.9 (2.4–11.5)
Cmin, mg/L 0.34 (0.23–0.87)
tmax, h 2.5 (1.5–6.0)
a
CL/F, L/h 12.7 (8.1–45.6)
Vd/F, L 36.2 (23.9–91.8)
t1/2, h 2.0 (1.4–3.1)
Desacetylrifampicinb
AUC0–24 h, mg  h/L 4.5 (0.0–7.1)
a
Cmax, mg/L 0.92 (0.0–1.5)
a
Cmin, mg/L 0.23 (0.0–0.39)
a
tmax, h 4.0 (0.0–6.0)
a
t1/2, h 1.94 (0.0–3.1)
a
Ratio of desacetylrifampicin to rifampicin
AUC0–24 h, mg  h/L 0.13 (0.0–0.26)
a
Cmax, mg/L 0.12 (0.0–0.21)
a
NOTE. Data are for study phase 1, in which patients received a combi-
nation of 400 mg of moxifloxacin administered once daily and 600 mg of
isoniazid and 450 mg of rifampicin administered 3 times weekly. AUC0–24 h, 24-
h area under the concentration-time curve; Cmax, highest observed plasma
concentration; Cmin, trough plasma concentration at 24 h after intake of study
medication; CL/F, total clearance; F, bioavailability; tmax, time at which Cmax
occurs; t1/2 elimination half-life; Vd/F, volume of distribution.
a Median and range.
b Desacetylrifampicin was not found in 4 subjects.
ative, fast-growing bacteria, the greatest bactericidal effect and
a decreased probability of development of resistance to fluo-
roquinolones occurs at AUC0–24 h:MIC and Cmax:MIC ratios of
100 and 10, respectively [17, 18, 23], in which AUC0–24 h
and Cmax values refer to total (i.e., both protein-bound and
unbound) concentrations [18–22]. For M. tuberculosis, which
is a slowly duplicating organism with the capacity for dormancy,
the pharmacodynamic parameters for optimal fluoroquinolone
activity are less well defined [21]. Recently, the activity of mox-
ifloxacin against M. tuberculosis has been found to be best de-
scribed by the ratio between AUC and MIC [17, 20]. Nuerm-
berger and Grosset [21] showed that even the potent quinolone
moxifloxacin, when used in TB treatment, does not reach the
ideal pharmacodynamic values for activity against gram-neg-
ative bacilli. Apart from this, an MPC has been defined [24],
above which plasma concentrations should be maintained to
prevent the emergence of resistance. It has been demonstrated
that only a few quinolones (moxifloxacin among them) achieve
brief periods of concentrations above the MPC [24]. In line
with this, previous research using an aerosol model concluded
that a moxifloxacin dosage of 800 mg per day (instead of 400
mg per day) is likely to achieve excellent antimicrobial activity
against M. tuberculosis and suppress drug resistance [38]. It
should be acknowledged that the clinical relevance of these
pharmacodynamic parameters in patients receiving multidrug
treatment of TB remains unclear. Presumably, the same inter-
action between rifampicin and moxifloxacin is occurring in the
murine model of TB treatment, and even so, the substitution
of moxifloxacin for isoniazid markedly improves the activity
of treatment. Therefore, it should be concluded that the clinical
relevance of the interaction between rifampicin and moxiflox-
acin is unknown at this time, and this applies to the admin-
istration of this drug combination to shorten the duration of
TB treatment, as well as for other clinical situations in which
this combination is used.
On the basis of the current study, we would propose that
follow-up pharmacokinetic studies be performed to assess
whether an increase in the dose of moxifloxacin to 600 mg or
800 mg compensates for the decrease in plasma levels caused
by (daily) coadministration of rifampicin. In addition, a study
of the pharmacokinetic interaction between moxifloxacin and
rifapentine (another rifamycin) is warranted, considering that
clinical trials involving this combination are underway. Finally,
additional research should be performed to explore the activity
and tolerability of higher doses of moxifloxacin, even in the
absence of rifampicin coadministration.
Our study is limited by the design of the study, which did
not allow discrimination between an effect on the moxifloxacin
metabolism of rifampicin or isoniazid. In addition, the MIC
and MPC values of M. tuberculosis for moxifloxacin were not
determined but were based on previous findings. Therefore,
pharmacodynamic ratios were partly derived. Furthermore, this
study was not designed to assess the impact of moxifloxacin
on the pharmacokinetics of rifampicin. Such an effect is not
expected, because moxifloxacin does not induce any
metabolism.
In conclusion, we showed a 31% decrease in exposure to
moxifloxacin when combined with intermittently administered
rifampicin and isoniazid in Indonesian patients with TB. This
finding is in agreement with data from healthy volunteers [36],
but the clinical relevance of this interaction has yet to be elu-
cidated. A higher dose of moxifloxacin may possibly overcome
the effect of rifampicin on the pharmacokinetics of moxiflox-
acin. Additional studies are warranted to assess the pharma-
cokinetics, dynamics, and tolerability of a higher dose of mox-
ifloxacin when combined with rifampicin or other rifamycin
derivatives.
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